<?xml version="1.0" encoding="UTF-8"?>
<p>To expedite the much-needed process of clinical trials for COVID-19 treatments, as mentioned previously, National Institute of Health (NIH) has collaborated with 16 companies, including AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Evotec, GlaxoSmithKline, Johnson &amp; Johnson, KSQ Therapeutics, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir Biotechnology. While big pharmaceutical companies usually work independently, these industries are now collaborating with different companies and laboratories in the fight against COVID-19. Such NIH industry partnership allows for standardized testing protocols and gives researchers access to better facilities for diagnoses, treatment, and vaccine testing [
 <xref rid="B125-diagnostics-10-00409" ref-type="bibr">125</xref>]. These industrial partners have promising potential results of their respective research in the fields of diagnostics, prevention, and treatment, as highlighted in 
 <xref rid="diagnostics-10-00409-t001" ref-type="table">Table 1</xref>.
</p>
